Hutchison MediPharma and Eli Lilly Sign New Discovery Deal
BEIJING - Shanghai-headquartered Hutchison MediPharma signed a new partnership agreement with Eli Lilly on drug discovery and development, according to MediPharma's chief executive officer
More from Archive
More from Scrip
• By
While CAR-NKs have pivoted towards autoimmune disease, the Norwegian biotech believes its unique platform can deliver in oncology
• By
The triple therapy improves lung function in the Phase III KALOS and LOGOS studies
• By
As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.